JC03 Rec'd PCT/PTO 1 3 OCT 2009

FORM PT (Rev. 11-2	000)	RCE ATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 689290-253						
		ED OFFICE (DO/EO/US) G UNDER 35 U.S.C. 371	U.S.APPLICATION NO. 44 kg wg 58 37 CFR 1.5)						
INTERNATIONAL APPLICATION NO. PCT/US2004/009289		INTERNATIONAL FILING DATE 15 April 2004	PRIORITY DATE CLAIMED 15 April 2003						
TITLE OF INVENTION DETERMINING CANCER-LINKED GENES AND THERAPEUTIC TARGETS USING MOLECULAR CYTOGENETIC METHODS									
APPLICANT(S) STROVEL, Jeffrey W., CAIN, Colyn B., HORRIGAN, Stephen K., and AUGUSTUS, Meena									
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
1. 🛛	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.								
2. 🔲	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.								
3. 🛛	This express request to being national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.								
4. 🖾	The US has been elected by the expiration of 19 months from the priority date (Article 31).								
5. 🛛	A copy of the International Application as filed (35 U.S.C. 371(c)(2))								
	a. is attached herewith (required only if not communicated by the International Bureau).								
	 b. ☐ has been communicated by the International Bureau. c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US) 								
6. 🗀									
	a. ☐ is attached hereto.								
	b. has been previously subm	has been previously submitted under 35 U.S.C. 154(d)(4).							
7. 🖾									
	a. ⊠ are attached hereto (required only if not communicated by the International Bureau).								
	b. have been communicated by the International Bureau.								
	c. have not been made; however, the time limit for making such amendments has NOT expired.								
3	d. have not been made and will not be made.								
8. 🗆	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).								
કે. ⊠	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
10. 🔲	An English language translation of the annexes to the International Preliminary Examination Report under								
	PCT Article 36 (35 U.S.C. 371(c)	(5)) .							
Items 1	1 to 20 below concern other doc	cument(s) or information included:							
11. 🔲	An Information Disclosure Statem	nent under 37 CFR 1.97 and 1.98.							
12. 🔲	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
13. 🖂	A FIRST preliminary amendment.								
14. 🔲	A SECOND or SUBSEQUENT preliminary amendment.								
15. 🔲	A substitute specification.								
16. 🗌	A change of power of attorney and/or address letter.								
17. 🔲	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821-1.825.								
18. 🛛	A second copy of the published international application under 35 U.S.C. 154(d)(4).								
19. 🔲	A second copy of the English language translation of the international application under 35 U.S.C. 15(d)(4).								
20. 🖾	Other items or information: Sequence Listing on Compact Disc plus statement under 37 C.F.R. 1.821(f)								

Form PTO-1390(Rev.11-2000) page 1 of 2

*U.S. APPLICATION NO. (If k	ATTORNEY'S DOCKET NUMBER 689290-253								
21. The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and									
International Search Report not prepared by the EPO and JPO \$300.00									
National Stage Searc		- 10							
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO									
International prelimin and all claims did not									
International prelimin and all claims satisfie									
EN	\$ 1000.00	r -							
Surcharge of \$130.00 fo months from the earliest	\$ 130.00								
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$					
Total Claims	45 - 20 =	25	X \$50.00	\$ 1250.00					
Independent Claims	13 - 3=	10	X \$200.00	\$ 2000.00					
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.0				\$ 0.00					
	\$ 4380.00								
Applicant claims sma above are reduced b	\$ 2190.00								
		SUBT	OTAL =	\$ 2190.00					
Processing fee of \$130.00 for furnishing the English translation later than 20 30 \$ months from the earliest claimed priority date (37 CFR 1.492(f))									
	\$ 2190.00								
Fee for recording the enclaceompanied by an appro	\$								
	\$ 2190.00								
	Amount to be refunded:	\$							
			<u> </u>	charged:	\$				
		2190.00 to cover the above f			•				
	b. Please charge my Deposit Account No. <u>03-0678</u> in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.								
	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>03-0678</u> . A duplicate copy of this sheet is enclosed.								
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit Card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
	NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
SEND ALL CORRESPON	ctober 2005								
ALAN J. GRANT, Esq. SIGNATURE Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein				alan Frant					
5 Becker Farr Roseland, Ne	-/-/								
, Noscialiu, Me	NT								
	N NUMBER : 33,389								